Association of Concomitant Use of Cholinesterase Inhibitors or Memantine With Cognitive Decline in Alzheimer Clinical Trials | Zendy

Richard Kennedy | Zendy; Gary Cutter | Zendy; Mackenzie E. Fowler | Zendy; Lon S. Schneider | Zendy

Open Access

Association of Concomitant Use of Cholinesterase Inhibitors or Memantine With Cognitive Decline in Alzheimer Clinical Trials

Author(s) -

Richard Kennedy,

Gary Cutter,

Mackenzie E. Fowler,

Lon S. Schneider

Publication year - 2018

Publication title -

jama network open

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.278

H-Index - 39

ISSN - 2574-3805

DOI - 10.1001/jamanetworkopen.2018.4080

Subject(s) - memantine , cholinesterase , concomitant , cognitive decline , medicine , alzheimer's disease , cognition , clinical trial , dementia , pharmacology , disease , psychiatry

Key Points Question Are cholinesterase inhibitors or memantine associated with cognitive outcomes in clinical trials for Alzheimer disease? Findings In this meta-analysis, participants receiving cholinesterase inhibitors or memantine had 1.4 points per year difference on the Alzheimer Disease Assessment Scale–cognitive subscale compared with those receiving neither medication, a significant difference that is roughly the same size as the expected effect of new therapeutic drugs being investigated in the clinical trials. Meaning Differences in the use of cholinesterase inhibitors and memantine between treatment and placebo groups of clinical trials may lead to the conclusion that a treatment is effective when it is not, or vice versa.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research